FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* CHANG LINDA L 2. Date of Event Requiring Stateme (Month/Day/Year) 11/10/2011		ement	3. Issuer Name and Ticker or Trading Symbol PHARMATHENE, INC [PIP]					
(Last) (First) (Middle) C/O PHARMATHENE, INC.,			Relationship of Reporting Pers (Check all applicable) Director	10% Owne	r (Mor	Amendment, Da ith/Day/Year)	te of Original Filed	
ONE PARK PLACE, SUITE 450			X Officer (give title below)	Other (spec below)	Appli	cable Line)	Group Filing (Check	
(Street) ANNAPOLIS MD 21401			SVP & CF	U	X	•	or One Reporting Person or More than One erson	
(City) (State) (Zip)								
Table I - Non-Derivative Securities Beneficially Owned								
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)	Form: Direc	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Benefi (Instr. 5)		Beneficial Ownership	
Restricted Stock			20,000(1)	D				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)								
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securiti Underlying Derivative Security		4. Conversion or Exercise Price of	5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	or Indirect (I) (Instr. 5)		
Option to Purchase	(2)	11/07/2011	Common Stock	170,000(2)	1.59	D		

Explanation of Responses:

- 1. The restricted stock vests at a rate of one-third per year, commencing on 11/7/2012, the first anniversary of the date of grant.
- $2. \ The options vested immediately with respect to 20,000 \ shares, with the remaining 150,000 \ shares vesting 25\% per year starting on 11/7/2012, the first anniversary of the date of grant.$

Remarks:

Exhibit List: Exhibit 24 - Confirming Statement

<u>/s/ Linda Chang</u> <u>11/18/2011</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

CONFIRMING STATEMENT

This Statement confirms that the undersigned has authorized and designated Jordan P. Karp, Jeffrey A. Baumel and Roland S. Chase (the "Authorized Signatories"), or any one or more of them, to execute and file on the undersigned's behalf all Forms 3, 4, and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of PharmAthene, Inc. The authority of the Authorized Signatories under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4, and 5 with regard to his/her ownership of, or transactions in, securities of PharmAthene, Inc., unless earlier revoked in writing. The undersigned acknowledges that Authorized Signatories are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

Dated:	11/18/2011						
Signed:	/s/ Linda L. Chang						
Print Name:	Linda L. Chang						